Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants

Vaccine

Volumn 20, Issue 23-24, 2002, Pages 2928-2932

  Esposito, Susanna ^a   Faldella, Giacomo ^b   Giammanco, Anna ^c   Bosis, Samantha ^a   Friscia, Ornella ^d   Clerici, Mario ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d GSK   (Italy)

Author keywords

DTaP HBV vaccine; Pertussis; Pre term infants

Indexed keywords

CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 5; BACTERIUM ANTIBODY; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS HIB HEPATITIS B VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS-HIB-HEPATITIS B VACCINE; HAEMOPHILUS VACCINE;

ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GESTATIONAL AGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PERTUSSIS; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VACCINATION; AGE; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; CELLULAR IMMUNITY; CHILD; IMMUNIZATION; IMMUNOLOGY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; NEWBORN; TIME;

AGE FACTORS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMAN; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IN VITRO; INFANT, NEWBORN; INFANT, PREMATURE; LYMPHOCYTE ACTIVATION; MALE; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; WHOOPING COUGH; HUMANS;

EID: 0037178305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00230-X     Document Type: Article

References (16)

1. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection
2. Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in 4-6-year-olds
3. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults
4. Outcomes of Bordetella pertussis infection in different age groups of an immunized population
5. Clinical development of a combined diphtheria, tetanus, acellular pertussis, and hepatitis B vaccine in Italy
6. The pre-term infant's antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine
7. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
8. Antibody responses and persistence 2 years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis
9. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines
10. Cell-mediated immunity and antibody responses to Bordetela pertussis antigens in children with a history of pertusis infection and in recipients of an acellular pertussis vaccine
11. Vaccine- and antigen-dependent types 1 and 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines
12. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine
13. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
14. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells
15. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens
16. Protection against Bordetella pertussis in mice in absence of detectable circulating antibody: Implications for long-term immunity in children